Intellia Therapeutics, Inc. (NTLA): Price and Financial Metrics


Intellia Therapeutics, Inc. (NTLA): $67.41

0.08 (+0.12%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NTLA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 492

in industry

NTLA Stock Summary

  • With a price/sales ratio of 78.63, Intellia Therapeutics Inc has a higher such ratio than 95.88% of stocks in our set.
  • With a year-over-year growth in debt of 113.9%, Intellia Therapeutics Inc's debt growth rate surpasses 90.5% of about US stocks.
  • The volatility of Intellia Therapeutics Inc's share price is greater than that of 92.84% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Intellia Therapeutics Inc, a group of peers worth examining would be CRBP, MTEM, FIXX, RCUS, and VYGR.
  • NTLA's SEC filings can be seen here. And to visit Intellia Therapeutics Inc's official web site, go to www.intelliatx.com.

NTLA Stock Price Chart Interactive Chart >

Price chart for NTLA

NTLA Price/Volume Stats

Current price $67.41 52-week high $92.00
Prev. close $67.33 52-week low $12.32
Day low $63.66 Volume 819,400
Day high $68.98 Avg. volume 1,615,511
50-day MA $66.91 Dividend yield N/A
200-day MA $43.29 Market Cap 4.57B

Intellia Therapeutics, Inc. (NTLA) Company Bio


Intellia Therapeutics a gene editing company, develops therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.


NTLA Latest News Stream


Event/Time News Detail
Loading, please wait...

NTLA Latest Social Stream


Loading social stream, please wait...

View Full NTLA Social Stream

Latest NTLA News From Around the Web

Below are the latest news stories about Intellia Therapeutics Inc that investors may wish to consider to help them evaluate NTLA as an investment opportunity.

What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.

So what did the stock market do today?

Sarah Smith on InvestorPlace | April 16, 2021

CRISPR Stocks: The Big Analyst Call Destroying CRSP, NTLA, EDIT Stocks Today

A "sell" rating is one thing, but a price target barely half of the Thursday close?

Vivian Medithi on InvestorPlace | April 16, 2021

Investing in CRISPR Stocks: Ultimate Genetic Editing Guide

The biotech space is on the verge of hypergrowth, thanks to a scientific breakthrough in genetic editing.

Luke Lango on InvestorPlace | April 15, 2021

Intellia Therapeutics Names Georgia Keresty, Ph.D., M.P.H., to Board of Directors

CAMBRIDGE, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the appointment of Georgia Keresty, Ph.D., M.P.H., to the company’s Board of Directors. “Dr. Keresty's experience as a scientific and operational leader in our industry will be a great asset to Intellia as we continue to advance our research programs, expand our manufacturing capabilities and move towards delivering potentially curative therapies to patients globally,” said Intellia President and Chief Executive Officer John Leonard, M.D. Dr. Keresty brings more than 35 years of pharmaceutical industry experience to Intellia’s board, including lea...

Yahoo | April 12, 2021

Leerink Partners Stick to Their Buy Rating for Intellia Therapeutics By Investing.com

Leerink Partners Stick to Their Buy Rating for Intellia Therapeutics

Investing.com | April 10, 2021

Read More 'NTLA' Stories Here

NTLA Price Returns

1-mo -1.42%
3-mo -7.14%
6-mo 170.94%
1-year 408.75%
3-year 210.50%
5-year N/A
YTD 23.92%
2020 270.82%
2019 7.47%
2018 -28.98%
2017 46.61%
2016 N/A

Continue Researching NTLA

Want to see what other sources are saying about Intellia Therapeutics Inc's financials and stock price? Try the links below:

Intellia Therapeutics Inc (NTLA) Stock Price | Nasdaq
Intellia Therapeutics Inc (NTLA) Stock Quote, History and News - Yahoo Finance
Intellia Therapeutics Inc (NTLA) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9408 seconds.